Xanodyne Pharmaceuticals Income Statement
View: Annual
| Dec 06 | Dec 05 | Dec 04 | |
|---|---|---|---|
| Revenue | 66.9 | 52.6 | 13.7 |
| Cost of Goods Sold | 13.5 | 10.1 | 4.9 |
| Gross Profit | 53.4 | 42.5 | 8.8 |
| Gross Profit Margin | 79.8% | 80.8% | 64.2% |
| SG&A Expense | 76.6 | 162.2 | 52.0 |
| Depreciation & Amortization | 2.4 | 1.4 | 0.5 |
| Operating Income | (23.2) | (119.7) | (43.1) |
| Operating Margin | -- | -- | -- |
| Nonoperating Income | 1.7 | 0.2 | 0.7 |
| Nonoperating Expenses | 6.8 | 2.9 | 0.0 |
| Income Before Taxes | (28.3) | (122.4) | (42.5) |
| Income Taxes | 0.0 | 0.0 | 0.0 |
| Net Income After Taxes | (28.3) | (122.4) | (42.5) |
| Continuing Operations | (28.3) | (122.4) | (42.5) |
| Discontinued Operations | 0.0 | 0.0 | 0.0 |
| Total Operations | (28.3) | (122.4) | (42.5) |
| Total Net Income | (28.3) | (122.4) | (42.5) |
| Net Profit Margin | -- | -- | -- |
| Diluted EPS from Total Net Income ($) | -- | -- | -- |
| Dividends per Share | -- | -- | -- |
